Bioinformatics Paradigms in Drug Discovery and Drug Development

被引:12
作者
Sharma, Ravinder [1 ]
Kaur, Gunpreet [2 ]
Bansal, Parveen [2 ]
Chawla, Viney [1 ]
Gupta, Vikas [2 ]
机构
[1] Baba Farid Univ Hlth Sci, Univ Inst Pharmaceut Sci & Res, Dept Pharmaceut Chem, Faridkot 151203, India
[2] Baba Farid Univ Hlth Sci, Univ Ctr Excellence Res, Faridkot 151203, India
关键词
Bioinformatics; Drug design; Drug target; Genomics; Proteomics; Molecular docking; 2-DIMENSIONAL GEL-ELECTROPHORESIS; SPECTROMETRY-BASED PROTEOMICS; THERAPEUTIC TARGET; MASS-SPECTROMETRY; PROTEIN; IDENTIFICATION; GENOMICS; PROGRESS; DESIGN; IMPACT;
D O I
10.2174/1568026623666221229113456
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Despite breakthroughs in medical sciences, drug development remains a time-consuming, expensive, challenging, and inefficient process with a high failure rate for novel therapeutic discoveries. Bioinformatics analysis can speed up drug target identification, drug candidate screening, and refining, but it can also help characterise adverse effects and anticipate drug resistance. Integrated genomics, proteomics, and bioinformatics have resulted in potent new tactics for resolving numerous biochemical problems and establishing new methodologies that result in new biomedical products. As a result, a new research trend emerged to demonstrate the mechanism of therapeutic action, forecast drug resistance, and uncover biomarkers for various disorders. The development of new medications is a complicated procedure. There are two basic approaches to drug design: ligand-based drug design and structure-based drug design. The study of protein structure and function was essential for drug development. Current techniques based on combinatorial approaches such as proteomics, genomics, bioinformatics, molecular docking, and mass spectrometry were applied. This article provides an overview of the combinatorial techniques of proteomics, genomics, and bioinformatics that aid in understanding the drug-creation process.
引用
收藏
页码:579 / 588
页数:10
相关论文
共 73 条
[1]   Proteornics and genomics: Perspectives on drug and target discovery [J].
Ahn, Natalie G. ;
Wang, Andrew H-J .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2008, 12 (01) :1-3
[2]   Combinatorial drug therapy for cancer in the post-genomic era [J].
Al-Lazikani, Bissan ;
Banerji, Udai ;
Workman, Paul .
NATURE BIOTECHNOLOGY, 2012, 30 (07) :679-691
[3]   Developments in toxicogenomics: understanding and predicting compound-induced toxicity from gene expression data [J].
Alexander-Dann, Benjamin ;
Pruteanu, Lavinia Lorena ;
Oerton, Erin ;
Sharma, Nitin ;
Berindan-Neagoe, Ioana ;
Modos, Dezso ;
Bender, Andreas .
MOLECULAR OMICS, 2018, 14 (04) :218-236
[4]  
Amaratunga D., 2007, MICROARRAYS COMPREHE, P87
[5]  
[Anonymous], 1997, GENOMICS, V45, P244
[6]   Properties and identification of human protein drug targets [J].
Bakheet, Tala M. ;
Doig, Andrew J. .
BIOINFORMATICS, 2009, 25 (04) :451-457
[7]  
Baldi A, 2010, SYST REV PHARM, V1, P99, DOI DOI 10.4103/0975-8453.59519
[8]   The properties of known drugs .1. Molecular frameworks [J].
Bemis, GW ;
Murcko, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) :2887-2893
[9]   Small Molecule Protein-Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles [J].
Blazer, Levi L. ;
Neubig, Richard R. .
NEUROPSYCHOPHARMACOLOGY, 2009, 34 (01) :126-141
[10]   Multitarget Drug Discovery and Polypharmacology [J].
Bolognesi, Maria Laura ;
Cavalli, Andrea .
CHEMMEDCHEM, 2016, 11 (12) :1190-1192